title: The effects of FK409 on pulmonary ischemia-reperfusion injury in dogs.
abstract: FK409 is the first spontaneous nitric oxide (NO) donor known to increase plasma cyclic guanosine 3',5'monophosphate levels. In this study, we evaluated the effect of FK409 on pulmonary ischemia-reperfusion injury in an in situ warm ischemia canine model. Fourteen dogs were divided into two groups, and the FK409-treated group was given 5 micrograms/kg per min FK409. Warm ischemia was induced for 3 h. The arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2), cardiac output (CO), left pulmonary vascular resistance (L-PVR), and endothelin-I (ET-I) were measured. A histologic study was performed, and polymorphonuclear neutrophils (PMNs) were also counted. The PaO2, SaO2, and L-PVR levels and PMNs after 30 min of reperfusion, ET-I after 2 h of reperfusion, and the 7-day survival rate were significantly (P < 0.05) better in the FK409-treated group than in the control group. The histologic damage was reduced in the FK409-treated group compared to the control group. FK409 appears to have a protective effect in ischemia-reperfusion injury of the lung.
authors.affiliation: Second Department of Surgery, Gunma University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Tanahashi
authors.forename: I
authors.initials: I
authors.lastname: Takeyoshi
authors.forename: M
authors.initials: M
authors.lastname: Aiba
authors.forename: S
authors.initials: S
authors.lastname: Ohwada
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
mesh_terms: D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D006152:Cyclic GMP / Q000096:biosynthesis; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D019332:Endothelin-1 / Q000097:blood; D007511:Ischemia / Q000188:drug therapy*; D008168:Lung / Q000098:blood supply* / Q000473:pathology; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D009574:Nitro Compounds / Q000627:therapeutic use*; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D011654:Pulmonary Edema / Q000209:etiology; D015427:Reperfusion Injury / Q000517:prevention & control*
chemical_list: D019332:Endothelin-1; D020030:Nitric Oxide Donors; D009574:Nitro Compounds; C061872:FK 409; D006152:Cyclic GMP; D010100:Oxygen